Intuitive Surgical INC

Intuitive Surgical, Inc. has updated its bylaws to align with new SEC universal proxy rules and enhance shareholder meeting procedures.

Intuitive Surgical announced robust second quarter 2026 financial results, driven by significant growth in worldwide procedures and system placements, leading to a 19% increase in revenue.

Intuitive Surgical has appointed Taylor Patton as Chief Commercial and Marketing Officer, effective July 1, 2026, succeeding Henry Charlton.

Intuitive Surgical announced robust first-quarter 2026 financial results, driven by significant growth in procedures and system placements.

Intuitive Surgical completed its acquisition of the da Vinci and Ion distribution business from ab medica and affiliates, expanding direct operations across Southern Europe.

Intuitive announced robust fourth-quarter 2025 financial results, driven by significant growth in da Vinci procedures and system placements, alongside a positive outlook for 2026 despite anticipated procedure growth deceleration.

Intuitive Surgical announces robust revenue and procedure growth in its Q2 2026 results, driven by strong demand for its da Vinci systems and instruments.

Intuitive Surgical reported strong Q1 2026 growth with revenue rising 23% to $2.77 billion, driven by increased da Vinci and Ion procedure volumes.

Intuitive Surgical's Q3 revenue increased 23% year-over-year, driven by procedure growth and system placements.

Intuitive Surgical, Inc. announced robust revenue and procedure growth for the second quarter of 2025, driven by increased system placements and procedure volumes, though gross profit margins faced pressure from new product launches and tariffs.

Intuitive Surgical's Q1 2025 results show a significant increase in revenue driven by procedure growth and system placements, despite facing potential tariff headwinds.

Intuitive Surgical's Q3 2024 results show significant revenue growth driven by increased procedure volumes and system placements, particularly for the da Vinci and Ion systems.

Intuitive Surgical achieved significant revenue and procedure growth in 2025, fueled by strong adoption of its da Vinci surgical systems, particularly the new da Vinci 5, and expanding use of the Ion endoluminal system.

Intuitive Surgical's 2024 10-K filing reveals a robust year marked by significant revenue growth, increased procedure volumes, and strategic advancements in its product offerings.

Intuitive Surgical's 10-K filing details its extensive subsidiary network, business strategy focused on minimally invasive care, and the competitive landscape it operates within.

Mark Brosius, EVP & Chief Mfg and Supply Cha of Intuitive Surgical Inc, sold 56 shares of common stock on July 30, 2026.

Mark Brosius, EVP & Chief Mfg and Supply Cha of Intuitive Surgical Inc, sold 84 shares of common stock on July 27, 2026.

David J. Rosa, Chief Executive Officer (CEO) and a Director of Intuitive Surgical Inc, reported multiple transactions in common stock on July 10, 2026.

Mark Brosius, EVP of Manufacturing and Supply Chain at Intuitive Surgical, sold 48 shares of common stock under a 10b5-1 plan.

Mark Brosius, EVP of Manufacturing and Supply Chain at Intuitive Surgical, sold 69 shares of common stock via a 10b5-1 plan.

Gary Loeb, EVP & Chief Legal and Compliance Officer at Intuitive Surgical, sold 400 shares of common stock.

Intuitive Surgical's 2026 proxy statement details a CEO transition, strong 2025 financial and operational growth, and proposals for the upcoming annual meeting.

Intuitive Surgical, Inc. files its definitive proxy statement with the Securities and Exchange Commission.

Intuitive Surgical's proxy statement details the agenda for the 2025 annual meeting, director nominations, executive compensation, and environmental, social, and governance (ESG) initiatives.

Intuitive Surgical, Inc. files its definitive proxy statement with the SEC.

Intuitive Surgical is asking stockholders to approve amendments to its incentive award plan and employee stock purchase plan at the 2024 annual meeting.

Vanguard Capital Management has reported a beneficial ownership of 7.49% in Intuitive Surgical Inc., holding over 26.6 million shares as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Intuitive Surgical Inc. following an internal realignment that disaggregated its holdings.